What frequent cannabis use may reveal about CHS warning signs

Cannabinoid Hyperemesis Syndrome-A Survey-Based Approach to Understanding Symptoms and Cannabis Use Patterns.

Cannabis and cannabinoid research • • Highly Relevant
🤖

AI Summary

This anonymous, social-media-based survey included 1,134 participants who reported symptoms associated with cannabinoid hyperemesis syndrome (CHS). Nearly all respondents (96.5%) used cannabis at least daily, and 45% reported using it six or more times per day around the time symptoms developed. Most had used cannabis for more than three years before symptom onset, and smoking flower and using vape cartridges were the most common consumption methods. Most participants obtained cannabis from licensed dispensaries, but the source of the product did not appear to change how CHS presented.

Early, or prodromal, symptoms most often occurred in the morning (63.1%) and commonly involved nausea and stomach pain. Women reported symptoms that were more frequent and lasted longer than those reported by men. The findings suggest that CHS is most often reported in the context of long-term, frequent use of inhaled delta-9-THC–dominant cannabis; vape-cartridge use was associated with a shorter time before symptoms developed. Because the study relied on self-reported information from people recruited through CHS-focused online communities, these patterns do not establish that cannabis products or specific methods directly cause CHS, but they may help users and clinicians recognize warning signs earlier.

💡 Key Findings

1
Nearly all respondents (96.5%) used cannabis daily or more often, and 45% reported using it six or more times per day around symptom onset.
Good
65%
2
CHS symptoms were most associated with long-term, frequent use of inhaled delta-9-THC–dominant cannabis; smoking flower and vape cartridges were the most commonly reported methods.
Good
65%
3
The early prodromal phase commonly involved morning nausea and stomach pain, with morning symptoms reported by 63.1% of participants.
Good
65%
4
Vape-cartridge use was associated with a shorter time to CHS symptom development, while the source of the cannabis product did not affect syndrome presentation.
Good
60%
5
Women reported more frequent and prolonged symptoms than men, suggesting that symptom patterns may differ by sex.
Good
60%

📄 Original Abstract

Cannabinoid hyperemesis syndrome (CHS) is increasingly being observed in emergency departments and is characterized by recurrent nausea and vomiting in some cannabis users. Despite its increasing prevalence, tools for early identification and intervention are lacking. This study aimed to improve our understanding of CHS by examining patterns of cannabis use and identifying symptom profiles of individuals suspected or diagnosed with CHS. By identifying the risk factors and initial warning signs, we can support earlier recognition, harm reduction, and intervention. An anonymous survey was distributed via social media to gather detailed, self-reported information about cannabis consumption methods, frequency of use, product sourcing, and CHS-related symptoms. Participants were recruited online through organic outreach to CHS-focused social media communities in late 2024. A total of 1134 participants were included in the final analysis. Most respondents reported smoking cannabis flower or using vape cartridges, although the use of edibles and concentrates were also described. The overwhelming majority of respondents (96.5%) used cannabis products at least daily, with approximately half (45%) using them six or more times per day around the time they developed CHS symptoms. Most of the respondents (61.9%) sourced cannabis from licensed dispensaries. The duration of cannabis use prior to symptom onset varied widely among participants, with nearly two-thirds (65.4%) reportedly used for more than 3 years before symptom development. During the prodromal (early) phase, symptoms clustered in the morning (63.1%) and the predominant complaints were nausea and stomach pain. Women reported more frequent and prolonged symptoms than men. Our findings suggest that CHS is most associated with long-term, frequent use of inhaled delta-9-tetrahydrocannabinol (Δ9-THC) dominant cannabis. The acquisition source of cannabis products did not affect the syndrome presentation. Although many different cannabis consumption methods were represented, smoking and vape cartridges were the most commonly reported. The use of vape cartridges was associated with a shorter time to the development of CHS symptoms. Increased awareness of these patterns could improve the early recognition and management of CHS.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.